Uma Sinha
CIK 1742587 · Chief Scientific Officer · last filed 2026-05-29
Uma Sinha is a Chief Scientific Officer who has filed 22 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing, for PROK, was dated May 29, 2026. Across all open-market trades the lifetime net is −$3.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.10M
3
22
-$3.27M
Holdings By Company
Recent Filings
22 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-29 | PROK | Grant (A) | — | $0 | EDGAR |
| 2025-06-02 | PROK | Grant (A) | — | $0 | EDGAR |
| 2024-06-03 | PROK | Grant (A) | — | $0 | EDGAR |
| 2023-07-03 | PROK | Grant (A) | — | $0 | EDGAR |
| 2022-07-13 | — | Grant (A) | +30,000 | $0 | |
| 2021-01-28 | — | Mixed | −306,525 | $0 | |
| 2021-01-15 | Eidos Therapeutics, Inc. (EIDX) Delisted | Sell (S) | −10,000 | -$1.24M | EDGAR |
| 2020-12-17 | BBIO | Grant (A) | — | $0 | EDGAR |
| 2020-12-04 | Eidos Therapeutics, Inc. (EIDX) Delisted | Sell (S) | −5,000 | -$450.2K | EDGAR |
| 2020-11-18 | BBIO | Exer (M) | +469 | $0 | EDGAR |